Ten companies soared higher on Wednesday, mirroring a broader market optimism, as investors cheered more earnings results and higher growth outlooks.

Meanwhile, Wall Street’s three main indices ended in the green, with the Nasdaq leading the gains by 0.59 percent. The Dow Jones increased by 0.10 percent while the S&P 500 jumped by 0.38 percent.

In this article, we spotlight the 10 top performers on Wednesday and detail the reasons behind their gains.

To come up with the list, we considered only the stocks with a $2 billion market capitalization and more than 5 million shares in trading volume.

10. Oklo Inc. (NYSE:OKLO)

Oklo rallied for a second day on Wednesday, jumping 6.45 percent to close at $102.86 apiece as investors took heart from its recent partnership with Siemens Energy to accelerate the deployment of Aurora powerhouses.

In a statement, Oklo Inc. (NYSE:OKLO) said it tapped Siemens Energy to begin engineering and design for a condensing SST-600 steam turbine, an SGen-100A industrial generator, and associated auxiliaries to support its Aurora powerhouse at Idaho National Laboratory (INL).

The power conversion system represents one of the major long-lead procurements required to commence power operations of the Aurora powerhouse.

In other news, Oklo Inc. (NYSE:OKLO) recently announced the results of its earnings performance for the third quarter of the year. During the period, the company widened its net loss by nearly 200 percent to $29.7 million from $9.96 million in the same period last year.

Operating loss also grew by 195.6 percent to $36.3 million from $12.28 million year-on-year.

“Aurora’s inherent safety allows us to use proven, commercially available power systems like Siemens Energy’s turbine technology. That design philosophy shortens timelines, lowers costs, and turns advanced nuclear into a deployable product. We believe this is a historic step forward for the advanced nuclear industry—a real-world purchase that demonstrates progress toward deployment and operation,” said Oklo Inc. (NYSE:OKLO) Chief Product Officer Alex Renner.

9. Block Inc. (NYSE:EXZ)

Block snapped a six-day losing streak on Wednesday, jumping 7.56 percent to close at $62 apiece as investor sentiment was bolstered by its strong financial growth outlook over the next three years.

By 2028, Block Inc. (NYSE:EXZ) expects gross profit to grow by mid-teens annually and reach $15.8 billion; adjusted operating income to increase 30 percent per annum to $4.6 billion; and adjusted earnings per share of low 30 percent annually to $5.50.

For next year alone, Block Inc. (NYSE:EXZ) targets to deliver 17 percent gross profit growth year-on-year to $11.98 billion, while adjusted operating income and adjusted earnings per share are projected to jump by more than 30 percent to $2.7 billion and $3.20, respectively.

Additionally, the company expects its non-GAAP cash flow to represent 20 percent of gross profit or $2.40 billion.

Guidance aside, the company also announced that it would raise its share repurchase program to $5 billion. As of the third quarter, it only has $1.1 billion remaining to spend.

“We’re moving faster with greater scale and efficiency, driving product velocity across Square and Cash App to serve more customers and help them participate in the modern economy,” said Block Inc. (NYSE:EXZ) COO and CFO Amrita Ahuja.

“Our guidance reflects the strength of our connected ecosystems and our ability to deliver compounding growth while expanding margins. We’ll continue to invest in innovation across our networks to sustain performance and create long-term value for our customers and shareholders.”

8. Hinge Health Inc. (NYSE:HNGE)

Hinge Health snapped a five-day losing streak on Wednesday, adding 8.57 percent to close at $44.10 apiece as investors cheered its higher growth outlook for full-year 2025 despite a mixed earnings performance in the third quarter.

In a statement, Hinge Health Inc. (NYSE:HNGE) said it is increasing its revenue guidance to a range of $572 million to $574 million, or a year-on-year growth of 47 percent at the midpoint.

For the fourth quarter alone, revenues are expected to be between $155 million to $157 million, or a year-on-year growth of 33 percent.

In the third quarter of the year, Hinge Health Inc. (NYSE:HNGE) swung to a net loss of $1.844 million from a $341,000 net income in the same period last year. Revenues, on the other hand, increased by 53 percent to $154 million from $100.6 million year-on-year.

“With healthcare costs rising dramatically, our mission to automate care delivery has never been more urgent,” Hinge Health Inc. (NYSE:HNGE) CEO Daniel Perez.

“This quarter we surpassed 1.5 million lifetime members, delivered year-over-year revenue growth of 53 percent, and generated record free cash flow. Our AI-powered platform is transforming care at scale, increasing engagement for our members and reducing healthcare costs for our clients.”

7. MP Materials Corp. (NYSE:MP)

MP Materials soared by 8.61 percent on Wednesday to close at $63.55 apiece as investors cheered a strong revenue performance in the third quarter of the year.

During the period, MP Materials Corp. (NYSE:MP) said revenues increased by 25 percent to $60.8 million from $48.68 million in the same period last year, primarily as a result of higher production of separated products, resulting in a greater mix of NdPr oxide and metal revenue in the current period.

Additionally, during the three months ended March 31, 2025, the company began  to recognize revenue from the sales of magnetic precursor products.

However, it swung to a net loss of $22.6 million from a $16.49 million net income in the same comparable period primarily due to a $46.3 million non-cash gain in the first quarter of 2024.

“MP Materials delivered strong execution across both our Materials and Magnetics divisions in the first quarter, marked by record NdPr oxide production and the initial sales of magnetic precursor materials,” said MP Materials Corp. (NYSE:MP) Chairman and CEO James Litinsky.

“Given recent events, it is now undeniable that the United States must reshore critical industries like rare earth magnetics—something we have been building toward since day one. “With rapidly intensifying engagement from both industry and government, MP Materials is leading this effort—underscoring our growing strategic and economic importance at a pivotal moment for American industrial policy,” he added.

6. Lumentum Holdings Inc. (NASDAQ:LITE)

Lumentum extended its winning streak to a 4th straight day on Wednesday to hit a new all-time high as investors after earning a bullish coverage from an investment firm.

During the session, the stock soared to its highest price of $280.22 before trimming gains to end the day just up by 8.69 percent at $268.92 apiece.

In a market note, Mizuho Securities initiated coverage on Lumentum Holdings Inc. (NASDAQ:LITE) with a “buy” recommendation and a price target of $290. The figure marks a 7.8 percent upside from its latest closing price.

Mizuho cited Lumentum Holdings Inc.’s (NASDAQ:LITE) position as a leading optical communications and laser supplier for data centers, telecommunications, and other markets, benefitting from a strong artificial intelligence demand.

Earlier this month, Lumentum Holdings Inc. (NASDAQ:LITE) also received a 60 percent price target from Wolfe Research, alongside an “outperform” rating on expectations that its indium phosphide laser solutions would highly benefit from the rapid development of the artificial intelligence industry.

In the first quarter of fiscal year 2026, Lumentum Holdings Inc. (NASDAQ:LITE) swung to a net income of $4.2 million from a $82.4 million net loss in the same period last year. Net revenues jumped by 58.4 percent to $533.8 million from $336.9 million year-on-year.

Encouraged by the results, the company further raised its net revenue outlook for the second quarter to a range of $630 million to $670 million, with diluted earnings per share of $1.30 to $1.50.

5. BellRing Brands, Inc. (NYSE:BRBR)

BellRing grew its share prices by 11.42 percent on Wednesday to close at $29.26 apiece following the results of its earnings performance for the fourth quarter of fiscal year 2025.

In an updated report, BellRing Brands, Inc. (NYSE:BRBR) dropped its net income by 17 percent to $59.6 million from the $71.7 million registered in the same period last year.

Net sales, however, jumped by 16.6 percent to $648.2 million from $555.8 million year-on-year, driven by 19.2 percent increase in volume and 2.6 percent decrease in price/mix.

For the full-year period, net profit decreased by 12 percent to $216.2 million from $246.5 million, while net sales increased by 16 percent to $2.3 billion from $1.996 billion.

“We delivered strong results in 2025, with sales up 16% driven by expanding household penetration, continued distribution gains and meaningful innovation performance,” said BellRing Brands, Inc. (NYSE:BRBR) CEO Darcy Davenport. “Premier is the #1 ready-to-drink protein shake brand, supported by strong brand equity, high repeat purchase rates, a scalable manufacturing platform and deep retail partnerships.”

Looking ahead, BellRing Brands, Inc. (NYSE:BRBR) targeted net sales and adjusted EBITDA to end at a range of $2.41 billion to $2.49 billion, and $425-$455 million, respectively.

4. PACS Group, Inc. (NYSE:PACS)

PACS Group soared to a new 52-week high on Wednesday as investors cheered the strong results of its earnings performance in the third quarter of the year.

During the period, the company said attributable net income increased by 235 percent to $52.4 million from $15.6 million, while total revenues grew by 27 percent to $1.3 billion from $1.02 billion year-on-year.

Encouraged by the results, PACS Group, Inc. (NYSE:PACS) expects revenues to be in the range of $5.25 billion to $5.35 billion for the full-year period.

“Our third-quarter and year-to-date 2025 revenue growth reflects the operational excellence across our portfolio that continues to drive demand for our services,” said PACS Group, Inc. (NYSE:PACS) Interim Chief Finance Officer Mark Hancock.

“We remain confident that our locally-led, centrally-supported model, coupled with enhanced compliance and controls, will increase our ability to deliver high-touch, high-quality care to our patients and strengthen our communities. With our exceptionally talented team, we are focused on continuing to execute our strategy to drive value for shareholders and the rest of the healthcare ecosystem,” he added.

3. Amentum Holdings Inc. (NYSE:AMTM) 

Amentum Holdings rallied for a second day on Wednesday, adding 17.19 percent to close at $25.57 apiece as investors took heart from an investment firm’s price target upgrade for its stock.

In a market note, UBS initiated a coverage on Amentum Holdings Inc. (NYSE:AMTM) with a price target of $25, but with a neutral rating.

The coverage reflected Amentum Holdings Inc.’s (NYSE:AMTM) stronger business  portfolio as compared with its counterparts, namely space infrastructure and front-end nuclear capabilities.

In a separate development, Amentum Holdings Inc. (NYSE:AMTM) also earned a bullish comment from Citron Research activist investor Andrew Left.

In a social media post, Left said that President Donald Trump “just made AMTM the most important company in America that nobody’s heard of….$55,” noting that the latter manages 90 percent of the US’ nuclear infrastructure for the Department of Energy.

2. Exact Sciences Corp. (NASDAQ:EXAS)

Exact Sciences climbed to a new two-year high on Wednesday, as investors loaded portfolios following reports that it set to be taken over by Abbott Laboratories in what could be its largest acquisition to date.

At intra-day trading, the stock soared to its highest price of $89.67 before trimming gains to end the day just up by 23.68 percent at $86.18 apiece.

According to Bloomberg, Exact Sciences Corp. (NASDAQ:EXAS) and Abbot Laboratories are now in advanced talks to acquire the medical testing company.

Citing people privy to the matter, Bloomberg said that the two parties are now discussing terms of the transaction, and that a potential deal could be announced in the coming weeks.

In other recent news, Exact Sciences Corp. (NASDAQ:EXAS) narrowed its net loss  for the third quarter of the year by 48.77 percent to $19.59 million from $38.24 million in the same period last year. Revenues grew by 20 percent to $850.7 million from $708.6 million year-on-year, on the back of strong revenues from screening and precision oncology segments.

Looking ahead, Exact Sciences Corp. (NASDAQ:EXAS) raised its revenue guidance for the full-year period to a range of $3.22 billion to $3.235 billion, from $3.13 billion to $3.17 billion previously.

Adjusted EBITDA was also targeted to be higher at $470 million to $480 million, versus $455 million to $475 million earlier.

1. Nuvation Bio Inc. (NYSE:NUVB)

Nuvation Bio saw its share prices jump to a new three-year high on Wednesday, as investors took path from an investment firm’s bullish coverage for its stock.

At intra-day trading, the stock soared to its highest price of $7.35 before paring gains to end the day just up by 48.96 percent at $7.15 apiece.

In its first coverage for Nuvation Bio Inc. (NYSE:NUVB), B. Riley gave the stock a “buy” recommendation with a price target of $12, or an X percent upside potential from its latest closing price, over confidence for the successful commercial rollout of the Ibtrozi (taletrectinib) drug to treat a type of lung cancer.

Having secured the approval of the Food and Drug Administration (FDA) in June, and the initial rollout of the drug, Nuvation Bio Inc. (NYSE:NUVB) said that it has already recorded nearly 204 patients that started the treatment.

B. Riley expects the listed firm to generate revenues as much as $168 million in 2026, and $302 million in 2027, from the said treatment.

In other news, Nuvation Bio Inc. (NYSE:NUVB) said that it widened its net loss in the third quarter of the year by 35 percent to $55.79 million from $41.21 million in the same period last year, pulled down by a 17 percent higher operating loss and expenses.

Revenues, on the other hand, soared by 1,704 percent to $13 million from only $727,000 in the same comparable period.

While we acknowledge the potential of NUVB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NUVB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.